1 drug(s) with this reaction
282 total reports
Malignant Neoplasm Progression has been reported as an adverse reaction across 1 drug(s) manufactured by Ipsen Biopharmaceuticals Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 282 adverse event reports mention malignant neoplasm progression in connection with Ipsen Biopharmaceuticals Inc products.
This page provides a breakdown of which Ipsen Biopharmaceuticals Inc drugs are most commonly associated with malignant neoplasm progression, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Ipsen Biopharmaceuticals Inc drugs have malignant neoplasm progression listed in their FDA adverse event reports, sorted by report count:
In addition to malignant neoplasm progression, the following adverse reactions have been reported across Ipsen Biopharmaceuticals Inc's drug portfolio:
1 drug(s) manufactured by Ipsen Biopharmaceuticals Inc have malignant neoplasm progression listed in their FDA adverse event reports: LANREOTIDE ACETATE.
There are a combined 282 reports of malignant neoplasm progression across 1 Ipsen Biopharmaceuticals Inc drug(s) in the FDA adverse event database.